Should I continue taking metformin and myoinositol during my break from letrozole (Femara)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Continuing Metformin and Myo-inositol During a Break from Letrozole

Yes, you should continue taking metformin and myo-inositol during your break from letrozole to maintain metabolic benefits and support potential spontaneous ovulation.

Benefits of Continuing Metformin and Myo-inositol

  • Metformin and myo-inositol can help maintain insulin sensitivity improvements achieved during your treatment, which is beneficial for women with PCOS regardless of active ovulation induction therapy 1
  • The combination of metformin and myo-inositol has shown significantly higher live birth rates compared to metformin alone in women with PCOS undergoing fertility treatments 2
  • Continuing these medications may help support spontaneous ovulation during your break from letrozole by maintaining the metabolic improvements already achieved 2

Evidence for Metabolic Benefits

  • Metformin helps reduce insulin resistance (HOMA-IR), fasting insulin levels (FINS), and improves lipid profiles (reducing TG and TC levels) in women with PCOS, which supports overall reproductive health 3
  • Myo-inositol complements metformin's action by further improving ovarian function parameters and hormonal balance 2
  • The combination therapy has been shown to improve menstrual cycle regularity, which may be particularly important during your break from letrozole 2

Considerations for Ovulation

  • While taking a break from letrozole to see if your HPO (hypothalamic-pituitary-ovarian) axis has recovered, maintaining metabolic support with metformin and myo-inositol may increase your chances of spontaneous ovulation 4
  • Studies show that myo-inositol may be particularly effective in women with normal BMI who are resistant to letrozole, potentially supporting ovarian function during your break 4
  • The combination of metformin and myo-inositol has demonstrated improvements in endometrial thickness and ovarian reserve function, which are important factors for successful conception 3

Important Caveats

  • If you do become pregnant during this break period, there is no evidence-based need to continue metformin for PCOS once pregnancy is confirmed unless you have other indications such as type 2 diabetes 5
  • Metformin crosses the placenta, resulting in umbilical cord blood levels as high or higher than maternal levels, which may have implications if pregnancy occurs 1
  • Long-term studies of children exposed to metformin in utero have shown concerning trends including higher BMI and waist circumferences, so discontinuation upon confirmed pregnancy should be discussed with your healthcare provider 1

Monitoring During Your Break

  • Regular monitoring of menstrual cycles during this period can help determine if spontaneous ovulation is occurring 3
  • If you experience improvements in cycle regularity while continuing metformin and myo-inositol, this may indicate improved ovarian function 2
  • After 1-2 months of your break, reassess with your healthcare provider to determine whether to restart letrozole based on whether spontaneous ovulation has occurred 4

By continuing metformin and myo-inositol during your break from letrozole, you maintain the metabolic benefits while giving your body an opportunity to demonstrate whether spontaneous ovulation can occur with these supportive medications alone.

References

Guideline

Metformin Safety When Trying to Get Pregnant

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.